| 摘要 |
PROBLEM TO BE SOLVED: To obtain the subject agent, whose bioavailability is improved by increasing water-solubility of JM216, a carcinostatic platinum complex. SOLUTION: This agent is a new JM216 suppository dosage form prepared by including amorphous JM216 in a pharmaceutical dosage form. The amorphous JM216 is obtained by grinding down powdered JM216 with aβ-cyclodextrin or polymer selected from the group consisting of gelatin, polyvinylpyrrolidinone and hydroxypropyl methyl cellulose, for a sufficient time to convert the JM216 into the amorphous state. The wt. ratio of the JM216 to theβ-cyclodextrin or polymer is (1:1) to (1:15). This can eliminate or alleviate a side effect, e.g. nausea or vomiting, which may be involved in the oral administration.
|
